Gene edited or engineered cells can reverse untreatable cancer. These therapeutics are limited to a minute fraction of the diseased population. Indee is developing a simple and scalable microfluidic technology that uses fluid dynamics to deliver gene editing molecules (eg: Crispr-Cas9) to cells with device manufacturing scales up to 10 million per year. We’re actively unlocking gene therapy for the masses.

Check out this interview with CEO Ryan Pawell

Be Part of the Revolution!

Next program starts Summer 2017. Apply by March 15th!